Pharmaceutical law is undoubtedly one of the specialties of the "Health Law" axis that best ensures the team's visibility. This field of research is, from a legal point of view, poorly exploited in France.
Projects
Hospital law can be described as the second marker of the team's disciplinary visibility. The books and manuals on this subject have been particularly praised. In recent years, hospital law has given rise to reflections on the organization of the health care system, on financing mechanisms and on liability. In the last few months, the subject has been in full mutation and the team has been able to take advantage of it to propose innovative publications.
Traditional medicine is probably the most surprising object of study. In the West, work on it is, to say the least, scarce. This lack of research does not mean that traditional medicine is not of interest to the researcher or the professional. The emergence of new medical techniques and the demands for a more alternative medicine have raised many legal questions.
The problem of violence in all its forms (physical, psychological, verbal, symbolic) has been the subject of a galloping inflation of legislation in France and abroad, the aim of which is to ensure better protection for victims, with diversified responses.
This project is led by Maria De Grandis (PhD, CR EFS), Sylvie Fernandes (PhD, DR EFS) and Stéphanie Morin (PhD, CR EFS), with the technical support of Alexandra Grimaldi (Research Assistant EFS), Cécile Durousseau (Research Assistant EFS) and Thomas Granier (Research Assistant EFS)
In this project we are interested in red blood cell diseases and the vascular abnormalities in which they may be involved, with a particular focus on dyserythropoiesis and blood cell interactions in the circulation. Initially we will concentrate our efforts on sickle cell disease as a pathological model, then we will extend our methodology to explore other diseases, notably membrane diseases, in which potential defects in erythropoiesis have never been examined.
Our transfusion research is focused on improving transfusion products, with RBC as the primary focus.